Bottom line
SWHFX vs QAAGZX: the short answer
SWHFX (Schwab Health Care Fund) and QAAGZX (T. Rowe Price Health Sciences Portfolio) share a meaningful slice of their top holdings — about 73% by weight.
But QAAGZX is far broader, holding 277 positions to 80 for SWHFX, so beyond the top names it adds exposure SWHFX doesn't have.
SWHFX is cheaper at 0.8% vs 0.86% — a difference of $6.00 a year per $10,000 invested.
Over five years, SWHFX returned +6.5% a year vs +4.1% for QAAGZX.
Updated Nov 19, 2026
SWHFX vs QAAGZX side by side
| SWHFX | QAAGZX | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Schwab | T. Rowe Price |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.8% | 0.86% |
| Annual cost per $10k | $80 | $86 |
| 10-yr cost on $10k (prospectus) | $990 | $1,061 |
| Max front load | — | None |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +15.9% | +18.1% |
| 5-yr return (annualized) | +6.5% | +4.1% |
| 10-yr return (annualized) | +8.1% | +9.0% |
| Best quarter | +15.3% | +23.4% |
| Worst quarter | −12.1% | −15.8% |
| Net assets (fund) | $642.3M | $751.7M |
| Number of holdings | 80 | 277 |
| Portfolio turnover | 41% | 65% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | SWHFX | QAAGZX | Difference |
|---|---|---|---|
| 2025 | +15.9% | +18.1% | −2.2% |
| 2024 | +0.1% | +1.7% | −1.6% |
| 2023 | +0.7% | +3.0% | −2.3% |
| 2022 | −4.7% | −12.5% | +7.8% |
| 2021 | +23.3% | +13.1% | +10.2% |
| 2020 | +12.9% | +29.6% | −16.8% |
| 2019 | +17.6% | +29.0% | −11.3% |
| 2018 | +4.0% | +1.1% | +2.9% |
| 2017 | +20.2% | +27.6% | −7.4% |
| 2016 | −4.4% | −10.5% | +6.1% |
Source: Fund prospectus bar charts
Holdings overlap
14 of SWHFX's top 25 holdings also appear in QAAGZX's top 25.
| Holding | SWHFX | QAAGZX |
|---|---|---|
| Eli Lilly & Co | 13.92% | 14.06% |
| Johnson & Johnson | 6.94% | 6.64% |
| AbbVie Inc | 5.81% | 5.12% |
| Merck & Co Inc | 4.98% | 4.00% |
| UnitedHealth Group Inc | 4.74% | 5.88% |
| Gilead Sciences Inc | 3.24% | 2.79% |
| Amgen Inc | 2.58% | 1.80% |
| Bristol-Myers Squibb Co | 2.44% | 2.12% |
| Thermo Fisher Scientific Inc | 2.16% | 2.53% |
| Stryker Corp | 2.11% | 1.78% |
| Vertex Pharmaceuticals Inc | 1.89% | 2.26% |
| Abbott Laboratories | 1.60% | 1.91% |
| Danaher Corp | 1.47% | 1.44% |
| Elevance Health Inc | 1.45% | 1.54% |
Source: SEC Form N-PORT
SWHFX top 10
- Eli Lilly & Co — 13.92%
- Johnson & Johnson — 6.94%
- AbbVie Inc — 5.81%
- Merck & Co Inc — 4.98%
- UnitedHealth Group Inc — 4.74%
- Gilead Sciences Inc — 3.24%
- Novartis AG — 2.92%
- Amgen Inc — 2.58%
- Bristol-Myers Squibb Co — 2.44%
- Medtronic PLC — 2.29%
QAAGZX top 10
- Eli Lilly & Co — 14.06%
- Johnson & Johnson — 6.64%
- Unitedhealth Group Inc — 5.88%
- Abbvie Inc — 5.12%
- Merck & Co. Inc. — 4.00%
- Gilead Sciences Inc — 2.79%
- Thermo Fisher Scientific Inc — 2.53%
- Vertex Pharmaceuticals Inc — 2.26%
- Bristol-myers Squibb Co — 2.12%
- Abbott Laboratories — 1.91%
FAQ
What is the difference between SWHFX and QAAGZX?
Which is cheaper, SWHFX or QAAGZX?
Should I own both SWHFX and QAAGZX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.